INVESTORS Annual Reports Financials Investor Presentations Shareholder Information Analysts Speak Events
LUPIN FOUNDATION
CAREERS Careers Overview Life at Lupin Campus Connect Learning & Development Current Openings P.L.E.D.G.E.
MEDIA Press Releases Downloadables
CONTACT US Contact Us Global Offices Partner With Us

FEATURED

2018 ▼
2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002

Lupin Announces Litigation Settlement with Forest for Memantine Tablets

November 02, 2010

Lupin Announces Final FDA Approval for Suprax® (Cefixime) Chewable Tablets

November 02, 2010

Lupin Net Profit up by 34 % in Q2, FY 2010-11 Robust Growth, Strong Profits

November 01, 2010

Lupin announces settlement with Warner Chilcott of Loestrin® 24 Fe and Femcon® Fe Patent Litigations

October 14, 2010

Lupin Announces Final FDA Approval of Generic Hyzaar® and Cozaar®

October 04, 2010

Lupin appoints Paul McGarty as President for Lupin Pharmaceuticals Inc.

August 03, 2010

Lupin Net Profit up by 40 % in Q1, FY 2010-11 Consistent Growth, Strong Profits

July 28, 2010

Lupin receives FDA approval for Famotidine for Oral Suspension

July 01, 2010

Lupin receives FDA approval for Lamotrigine tablets

June 04, 2010

Lupin FY 2009-10 Consolidated Net Profits up 36% to Rs 6816 mn

May 05, 2010

Lupin receives FDA approval for Imipramine Pamoate Capsules

April 20, 2010

Lupin launches Hyalgan® in India Marks foray into the Orthopaedics segment

March 25, 2010

Lupin receives FDA tentative approval for Eszopiclone tablets

March 20, 2010

Lupin receives US FDA approval for Amlodipine / Benazepril capsules

February 08, 2010

Lupin Net Profit up 38 % - Q3, FY 2009-10

January 29, 2010

Lupin Strengthens its Board; Appoints Three Independent Directors

January 28, 2010

Lupin receives US FDA approval for Perindopril Erbumine Tablets

January 28, 2010

Lupin receives US FDA tentative approval for Memantine HCl tablets

January 20, 2010